Cover Image
市場調查報告書

老年性黃斑部病變 (AMD) 與其他視網膜疾病:全球治療藥物市場 2017-2027年

Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027: Outlook & Analysis for Ophthalmic Drugs for Age-Related Macular Degeneration, Dry AMD, Wet AMD, Diabetic Macular Edema, Retinal Vein Occlusion & Geographic Atrophy

出版商 Visiongain Ltd 商品編碼 290418
出版日期 內容資訊 英文 196 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
老年性黃斑部病變 (AMD) 與其他視網膜疾病:全球治療藥物市場 2017-2027年 Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027: Outlook & Analysis for Ophthalmic Drugs for Age-Related Macular Degeneration, Dry AMD, Wet AMD, Diabetic Macular Edema, Retinal Vein Occlusion & Geographic Atrophy
出版日期: 2017年07月17日 內容資訊: 英文 196 Pages
簡介

全球視網膜疾病治療藥物市場規模預計將在2017年來到119億8,000萬美金。2017年至2027年預計將達成更強大的收益。

本報告針對老年性黃斑部病變 (AMD) 等視網膜疾病藥物市場進行調查、銷售動向、技術動向、市場機會等收益預測,次市場 (濕型AMD、乾型AMD、DR (糖尿病視網膜症) ) 動向也將彙整如後。

第1章 調查概要

第2章 全球老年性黃斑部病變 (AMD) 與其他視網膜疾病市場

  • 視網膜疾病是什麼
  • 視網膜疾病種類
  • AMD與其他視網膜疾病診斷、治療
  • 約2億人患有AMD?
  • 1億人以上換有DR (糖尿病視網膜症)
  • 最初的RVO (視網膜靜脈阻塞症) 推計有1,600萬患者人口
  • 到2027年為止市場將急速發展
  • Eylea是市場領導治療藥物
  • Regeneron的市場比例很高
  • 市場最大的疾病領域是?

第3章 視網膜疾病市場的次市場

  • 濕型AMD依然是市場主要收益來源
  • 濕型AMD:血管產生過程明確的定義了藥物標的
  • 乾型AMD:阻止視網膜色素上皮 (RPE) 細胞損壞或無效的需求
  • DR (糖尿病視網膜症) :以糖尿病黃斑浮腫 (DME) 為目標的臨床矚目焦點
  • Lucentis 、 Eylea 的延長試驗顯示在其他新領域也許有新可能性
  • 全面預測

第4章 老年性黃斑部病變 (AMD) 與其他視網膜疾病市場認證產品

  • 現在的產品是否將獨佔市場到2027年
  • Lucentis:市場第2大治療藥物
  • Eylea:能否位居首位?
  • Avastin:未被正式承認但最常使用的產品
  • Visudyne (Valeant/Novartis): 銷售額在調查期間可能減少
  • Jetrea (ThromboGenics/Novartis): 2013年的發售不如預期

第5章 濕型AMD候補藥物

  • 主要候補藥物
  • Fovista (Ophthotech Corporation/Novartis) :下個重點?
  • 候補藥物標的中其他成長因素
  • Conbercept (Chengdu Kanghong Biotech): 作為濕型AMD藥物在中國發售
  • 新抗VEGFR劑或輸送系統是必要的嗎?
  • 活性抗炎症技術化的新輸送系統
  • 濕型AMD藥物開發研究中的其他目標
  • 再生醫療技術

第6章 乾型AMD候補藥物

  • 乾型AMD明顯進步的是哪項?
  • MC-1101 (MacuCLEAR)
  • ACU-4429 (Acucela) :第三期試驗中視覺循環調控子
  • 乾型AMD在補體抑制方面的厚望
  • 副腎皮質類固醇 (皮質類固醇) :以乾型AMD症等炎症為目標
  • 神經防護作用:現代醫療的最大目標之一
  • 再生醫療:乾型AMD最大疾病目標之一
  • 乾型AMD其他治療法

第7章 糖尿病性視網膜症 (DR) 的候補藥物

  • Ozurdex/Posurdex (Allergan) :為一般DME患者通過認可
  • Lucentis:DR的挑戰?
  • 新型抗VEGF的追加
  • DR開發中的類固醇
  • DR開發中的其他製品

第8章 地區市場分析

  • 最有可能擴大收益的市場
  • 美國:視網膜疾病大型市場
  • 日本:安定的市場可能性
  • 歐洲5國:高齡化帶動市場成長
  • BRIC各國:市場最大的成長牽引者

第9章 產業、市場定性分析

  • 強項
  • 弱點
  • 機會
  • 威脅
  • 社會性
  • 技術性
  • 經濟面
  • 政治面

第10章 結論

  • Lucentis老舊化:接近終點?
  • Lucentis vs. Eyla vs. Avastin:抗VEGF市場3種方向性
  • 濕型以外症狀的重要性增加
  • 乾型市場具有極大潛力
  • Fovista是候補藥物中最有希望的
  • 視網膜疾病依舊是眼疾主要分野

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0213

Title:
Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027
Outlook & Analysis for Ophthalmic Drugs for Other Retinal Diseases Including Age-Related Macular Degeneration (ARMD), Dry AMD, Wet AMD, Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO) & Geographic Atrophy (GA).

Macular Degeneration, Diabetic Retinopathy and Other Retinal Diseases - our new study reveals trends, R&D progress, and predicted revenues

Where is the Retinal disease therapeutic market heading? If you are involved in this sector you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead

Our 169-page report provides 80 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Retinal Disease market. See how to exploit the opportunities.

Forecasts from 2017-2027 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market, you find revenue forecasts to 2027 for the following submarkets:

  • Wet age-related macular degeneration (wAMD)
  • Dry AMD (dAMD)
  • Diabetic retinopathy (DR)
  • Other retinal diseases (grouped forecast).

Our investigation discusses what stimulates and restrains business. Understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.

Predictions of leading products' sales - what's possible for those eye drug revenues?

How will individual retinal medicines perform from 2017 to 2027 at world level? Our study forecasts revenues of four prominent brands:

  • Lucentis
  • Eylea
  • Avastin
  • Visudyne

Discover how high revenues can go. See what's happening, understanding the trends, challenges and opportunities.

Our analysis also divides the main global forecast into geographical markets.

What are the prospects in the leading regions and countries?

You will discover individual revenue forecasts for 10 leading national markets from 2017-2027:

  • United States (US)
  • Japan
  • Germany, France, the UK, Italy and Spain (EU5 group)
  • Brazil, Russia, India and China (BRIC countries).

Leading companies and the potential for market growth

Our analysis forecasts that the world market for retinal drugs will reach $11.98bn in 2017. It will achieve strong revenue expansion from 2017 to 2027. Our report reveals how high sales will go over the next 10 years.

Research and development - assess innovation, trends and possibilities

There you can also investigate R&D, appraising technological, clinical and commercial possibilities.

In our study explore the research and development in slowing vision loss and restoring sight. You can examine these advances and others:

  • Combination therapies, including neovascularisation disrupters
  • Angiogenesis inhibition by blocking pericyte recruitment
  • Anti-inflammatory mechanisms (inc. corticosteroids)
  • Targeting VEGF and PDGF (inc. receptors, kinases and angiogenesis pathways)
  • Monoclonal antibodies, mAb fragments, DARPins (designed ankyrin repeat proteins) and visual cycle modulators.

Explore the other agents and possibilities, too, including these:

  • Oligonucleotides and siRNA therapy
  • Anti-integrin oligopeptide treatment
  • Complement factor inhibition and serotonin modifiers
  • Angiotensin receptor blockers and converting enzyme inhibitors
  • Biosimilars and other follow-on biologicals and next generation therapeutics
  • Regenerative medicine, neural stem cells (NSCs), cellular and gene therapies.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the Biosimulation market and leading companies. You will find data, trends and predictions.

Get our report today Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027: Outlook & Analysis for Ophthalmic Drugs for Other Retinal Diseases Including Age-Related Macular Degeneration (ARMD), Dry AMD, Wet AMD, Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO) & Geographic Atrophy (GA). Avoid missing out - get our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Why You Should Read This Report
  • 1.2. How This Report Delivers
  • 1.3. Main Questions Answered by This Analysis
  • 1.4. Who Is This Study For?
  • 1.5. Methods of Research and Analysis
  • 1.6. Frequently Asked Questions (FAQs)
  • 1.7. Some Associated Reports
  • 1.8. About Visiongain

2. World AMD and Other Disease Market, 2016

  • 2.1. What are Retinal Diseases?
  • 2.2. Types of Retinal Diseases
  • 2.3. Diagnostics and Treatments for AMD and Other Retinal Diseases
  • 2.4. Nearly 200 Million People with AMD?
  • 2.5. Over 100 Million with DR
  • 2.6. First RVO Estimates Suggest Patient Population of 16 Million
  • 2.7. Market to Make Rapid Pace to 2027
  • 2.8. Eylea Stood as the Leading Drug in the Market
  • 2.9. Regeneron the Leading Presence in the Market
  • 2.10. Which are the Most Significant Disease Areas for the Market?

3. Retinal Disease Market Subsectors, 2016

  • 3.1. Wet AMD Still the Main Source of Revenue in the Market
  • 3.2. Wet AMD: Angiogenic Processes Offer Well-Defined Drug Targets
    • 3.2.1. Revenue Forecasting for Wet AMD segment, 2016-2027
  • 3.3. Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
    • 3.3.1. Dry AMD Segment to Emerge in the Forecast Period
  • 3.4. DR: Coming Into Clinical Focus, with DME the Main Target
    • 3.4.1. Segment to Grow in Importance as Diabetes Epidemic Continues
  • 3.5. Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
  • 3.6. Projections for All Segments, 2016-2027

4. Approved Products in the AMD and Other Retinal Diseases Market, 2016-2027

  • 4.1. Will the Current Products Dominate the Market Through 2027?
  • 4.2. Lucentis: Second Leading Drug in the Market
    • 4.2.1. Positive Revenue Growth Shown in Past: 2012-2016
    • 4.2.2. Shadow of Avastin Still Hangs Over Lucentis
    • 4.2.3. CATT Study Results: Clinical Differences Still Have Yet to Emerge
    • 4.2.4. Eylea: The Bigger Threat to Lucentis?
    • 4.2.5. Extending the Label, Widening the Battleground: Lucentis Moves Into DME and Beyond
    • 4.2.6. Improving Cost and Compliance for Lucentis
    • 4.2.7. Lucentis Revenue Forecast 2016-2027
    • 4.2.8. Will Loss of Physician Goodwill Harm Lucentis' Growth?
  • 4.3. Eylea: Holds the Throne?
    • 4.3.1. Increasing Revenue Growth in Past: Outside US Sale Amplified
    • 4.3.2. VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
    • 4.3.3. First Wave of Eylea's Expansion Finally Beginning to Break?
    • 4.3.4. Eylea into DME and Other New Indications
    • 4.3.5. Eylea Revenue Forecast 2016-2027
    • 4.3.6. How Far Can Eylea's Momentum Carry It?
  • 4.4. Avastin: No Formal wAMD Approval but Still the Most-Used Product
    • 4.4.1. Past Revenue illustrates Increasing Use of Avastin for wetAMD
    • 4.4.2. Judicial Review Averted in the UK by Price Adjustment
    • 4.4.3. Multiple Attempts to Block Off-Label Avastin Since 2007
    • 4.4.4. Roche and Novartis Challenge CATT's Headline Conclusions
    • 4.4.5. Will Eylea/Zaltrap Affect Avastin's Place in the Market?
    • 4.4.6. Avastin Revenue Forecast, 2016-2027
    • 4.4.7. Will Anything Dislodge Avastin from its Central Position?
  • 4.5. Visudyne (Valeant/Novartis): Declining Sales throughout the Forecast Period
    • 4.5.1. Visudyne Revenue Forecast, 2016-2027
  • 4.6. Jetrea (ThromboGenics/Novartis): Disappointing Launch in 2013

5. Pipeline for Wet AMD Segment, 2016-2027

  • 5.1. The Leading Pipeline Candidates
  • 5.2. Fovista (Ophthotech Corporation/ Novartis): The Next Big Thing?
    • 5.2.1. Three Phase 3 Trials to Confirm Fovista's Outstanding Phase 2 Results
    • 5.2.2. Ophthotech Goes Public to Fund Phase 3 Effort
    • 5.2.3. Ophthotech Partners with Novartis for Fovista
    • 5.2.4. Improving Angiogenesis Inhibition by Blocking Pericyte Recruitment
    • 5.2.5. The Move toward Combination Therapies
    • 5.2.6. Biosmiliars of Lucentis: FYB201 & PF-582
    • 5.2.7. TK001/sevacizumab (Jiangsu T-Mab Biopharma)‘s recombinant humanized anti-VEGF monoclonal antibody
    • 5.2.8. Roche's RG7716 (RO-6867461), an anti- VEGF A monoclonal antibody
    • 5.2.9. Opthea's OPT-302, a VEGFR inhibitor
    • 5.2.10. Daiichi Sankyo's DS7080, an angiogenesis inhibitor
  • 5.3. Other Growth Factor Targets in the Pipeline
    • 5.3.1. Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop
    • 5.3.2. Allergan and Molecular Partners: Preclinical DARPin Hits VEGF and PDGF
    • 5.3.3. NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options
    • 5.3.4. Regeneron's REGN910-3 (Nesvacumab + Aflibercept) and REGN910 (Nesvacumab)
    • 5.3.5. iSONEP (Lpath): Pfizer Interested in Anti-S1P Monoclonal Antibody
  • 5.4. Conbercept (Chengdu Kanghong Biotech): Launched in China for wAMD
    • 5.4.1. A Chinese Competitor: Where Will Conbercept Fit In?
    • 5.4.2. Binding Affinity Comparable to Eylea
  • 5.5. Do We Need New Anti-VEGFR Agents or Delivery Systems?
    • 5.5.1. Abicipar Pegol (Allergan): Novel Protein with Extended Half-Life
    • 5.5.2. Brolucizumab (Alcon): Single-Chain Monoclonal Antibody Fragment
    • 5.5.3. PDS 1.0 (ForSight Vision4): A New Option for Lucentis Delivery
    • 5.5.4. NT-503 (Neurotech): New Delivery Platform for Anti-VEGF Agent
    • 5.5.5. Pan-90806 (PanOptica): Anti-VEGF Eyedrop
    • 5.5.6. Iontophoretic Delivery: EyeGate Pharmaceuticals Leading the Way
  • 5.6. Novel Delivery Systems to Rejuvenate Anti-Inflammatory Approaches
    • 5.6.1. Verisome System and IBI-30089 (Icon Bioscience)
  • 5.7. Other Targets Under Investigation in wAMD Drug Development
    • 5.7.1. Are Kinase Inhibitors Still a Going Concern in wAMD?
    • 5.7.2. Pazopanib (GlaxoSmithKline) and TG100801 (Sanofi): Two Eyedrop Kinase Inhibitors Drop Out of the Running
    • 5.7.3. X-82 Pill (Tyrogenex): Dual Kinase Inhibitor
    • 5.7.4. Factor C5: A More Promising Target Addressed by Zimura (Ophthotech) and LFG316 (Novartis)
    • 5.7.5. Integrins: Another Blockable Component of the Neovascularisation Cascade?
    • 5.7.6. Luminate (Allegro Ophthalmics): Novel Anti-Integrin Oligopeptide
    • 5.7.7. SF0166 (SciFluor Life Sciences): an integrin αvβ3 inhibitor for Wet AMD
    • 5.7.7. Jetrea (ThromboGenics/Novartis): Can Pharmacologic Vitreolysis Help wAMD Patients?
    • 5.7.8. Novel Anti-Angiogenic Treatments in Development: Ora Bio's ORA102 and CoMentis' ATG003
    • 5.7.9. Zybrestat (Mateon Therapeutics Oxigene, formerly OxiGENE): New Mechanism of Action Offers Way to Disrupt Neovascularisation
    • 5.7.10. Alcon's LMG324 and LHA510 for wAMD
    • 5.7.11. hI-con1 (Iconic Therapeutics), VII-IgGFc chimeric protein targeting tissue factor
    • 5.7.12. Synthetic Biologics: Oligonucleotides and SiRNAs for wAMD
  • 5.8. Regenerative Medicine Approaches
    • 5.8.1. Allogeneic Stem Cells (Mesoblast): Potential Synergistic Treatment for Use alongside Lucentis
    • 5.8.2. AVA-101 and AVA-201(Avalanche Biotechnologies): Ocular BioFactory for wAMD
    • 5.8.3. RetinoStat (Oxford BioMedica): LentiVector Technology to Deliver Anti-Angiogenic Genes
    • 5.8.5. Gene Therapy (RGX-314) for Neovascular AMD
    • 5.8.6. Stem cell therapy with Pfizer's PF05206388
    • 5.8.7. Diffusion Pharmaceuticals' Palomid-529
    • 5.8.8. MT-0814 (Mitsubishi Tanabe Pharma), CC chemokine receptor 3 antagonist for AMD
    • 5.8.9. Undisclosed MoA of Boehringer Ingelheim's BI 144807 for Wet AMD

6. Pipeline for Dry AMD Segment, 2016

  • 6.1. Who Will Achieve the Big Breakthrough in Dry AMD?
  • 6.2. MC-1101 (MacuCLEAR): Leading the Pack?
    • 6.2.1. Increasing Choroidal Blood Flow with Repurposed Product
    • 6.2.2. Novel Endpoints in Phase 3 Study
    • 6.2.3. Can MacuCLEAR Make It?
  • 6.3. ACU-4429 (Acucela): Visual Cycle Modulator in Phase 3
    • 6.3.1. Disappointing results of Phase 2/3 trial
  • 6.4. High Hopes for Complement Inhibition in Dry AMD
    • 6.4.1. Lampalizumab (Roche): The Big News of ARVO 2013
    • 6.4.2. MAHALO Study Indicates GA Progression Slowed by Lampalizumab
  • 6.5. Corticosteroids: Targeting Inflammation's Role in Dry AMD Pathogenesis
    • 6.5.1. Iluvien (Alimera Sciences): Study terminated
    • 6.5.2. AGN208397 (Allergan): New Potent Steroid Expected to Undergo Trials in Dry AMD
  • 6.6. Neuroprotection: One of Modern Medicine's Holy Grails
    • 6.6.1. Tandospirone (Alcon): Not effective in GA
    • 6.6.2. Neurotech's Renexsus: Possibly Promising Data in Dry AMD Studies
    • 6.6.3. Novadur (Allergan): Possible Efficacy with Longer Duration of Action
  • 6.7. Regenerative Medicine: Dry AMD One of the Biggest Disease Targets
    • 6.7.1. MA09-hRPE Cellular Therapy (Ocata Therapeutics): Signs of Efficacy in Landmark ESC Human Trial
    • 6.7.2. HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space
    • 6.7.3. Stemedyne-RPE (Stemedica Cell Technologies): Low-Oxygen Cells for Dry AMD Repair
    • 6.7.4. OpRegen (Biotime): Stem Cell leader with Dry AMD Interests
    • 6.7.5. First iPSC Trial in Japan in Dry AMD Patients
    • 6.7.6. Ophthotech's Zimura for Geographic Atrophy
    • 6.7.7. Gene Therapies Less Prominent Than Stem Cells in Dry AMD
  • 6.8. Other Treatments for Dry AMD

7. Pipeline for Diabetic Retinopathy Segment, 2016

  • 7.1. Ozurdex/Posurdex (Allergan): Approved for General DME Patient Population
  • 7.2. Lucentis: The Game Changer for DR?
  • 7.3. New Anti-VEGF Additions
    • 7.3.1. Is Eylea Better than Lucentis and Avastin for DME?
  • 7.4. Steroids in Development for DR
    • 7.4.1. Iluvien (Alimera/pSivida): New Option in European Markets
    • 7.4.2. A New Hope? Optina (Ampio Pharmaceuticals)
    • 7.4.3. Betamethasone Microsphere (Santen): Late-Stage Steroid Candidate
    • 7.4.4. Clearside Biomedical's CLS-TA/ CLS1004
    • 7.4.5. IBI-20089 (Icon Bioscience): Sustained-Release Formulation of Triamcinolone Acetonide
    • 7.4.6. Kala Pharmaceuticals' KPI-121
  • 7.5. Other Products in Development for DR
    • 7.5.1. Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation
    • 7.5.2. Vitreosolve (Innovations in Sight): Will a Phase 3 Trial Be Initiated?
    • 7.5.3. TriLipix (Abbott): No New Development for Promising Drug
    • 7.5.4. Jetrea (ThromboGenics /Novartis): Possibilities in DME?
    • 7.5.5. SF0166 (SciFluor Life Sciences): an integrin αvβ3 inhibitor for DME
    • 7.5.6. Pan-90806 (PanOptica): Anti-VEGF Eyedrop
    • 7.5.7. Teprotumumab (Horizon Pharma): an insulin-like growth factor-1 receptor antagonist
  • 7.6. Undisclosed MoA of Boehringer Ingelheim's BI 1026706 for DME

8. Regional Market Breakdown, 2016

  • 8.1. Which Markets Hold the Most Revenue Growth Potential?
  • 8.2. The US: Leading Market for Retinal Diseases
  • 8.3. Japan: Strong Market Potential
  • 8.4. EU5: Ageing Populations to Drive Market Growth
  • 8.5. BRIC Nations: The Biggest Growth Driver for the Market

9. Qualitative Industry and Market Analysis, 2017-2027

  • 9.1. Strengths: The Most Dynamic Area of the Ophthalmics Market
  • 9.2. Weaknesses: Heavily Dependent on Anti-VEGF Approach
  • 9.3. Opportunities: New Markets and R&D Synergies
  • 9.4. Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
  • 9.5. Social: Low Diagnosis, Low Compliance
  • 9.6. Technological: Innovation for the Eye
  • 9.7. Economic: Off-Label Treatment and Reimbursement Issues
  • 9.8. Political: The Demography and Diabetes Challenges

10. Report Conclusions

  • 10.1. The Age of Lucentis: Nearing Its Conclusion?
  • 10.2. Lucentis vs. Eylea vs. Avastin: The Three-Way Anti-VEGF Market
  • 10.3. Indications Outside Wet AMD to Gain in Importance
  • 10.4. Dry AMD Market Has Huge Potential
  • 10.5. Fovista Most Prominent Among the Pipeline Candidates
  • 10.6. Retinal Diseases to Continue to Be the Leading Area of Ophthalmics
  • Associated Visiongain Reports
  • Glossary
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Report Evaluation Form

List of Figures

  • Figure 2.1: Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), 2016-2027
  • Figure 2.2: Market Breakdown by Product Revenue ($bn), Market Share (%), 2016
  • Figure 2.3: Market Breakdown by Company: Market Share (%), 2016
  • Figure 2.4: Leading Causes of Blindness Worldwide, Proportion of Total (%), 2010
  • Figure 2.5: Leading Causes of Visual Impairment (Inclusive of Blindness) Worldwide, Proportion of Total (%), 2010
  • Figure 3.1: Market Breakdown by Disease Segment: Revenues ($bn), 2016
  • Figure 3.2: Market Breakdown by Disease Segment: Market Share (%), 2016
  • Figure 3.3: Wet AMD Segment Forecast: Revenue ($bn), 2016-2027
  • Figure 3.4: Dry AMD Segment Forecast: Revenue ($bn), 2016-2027
  • Figure 3.5: DR Segment Forecast: Revenue ($bn), 2016-2027
  • Figure 3.6: Retinal Diseases Market Breakdown by Segment: Revenue ($bn), 2016-2027
  • Figure 3.7: Retinal Diseases Market Breakdown by Segment: Revenue ($bn), 2016, 2021 and 2027
  • Figure 3.8: Market Breakdown by Disease Segment: Market Share (%), 2021
  • Figure 3.9: Market Breakdown by Disease Segment: Market Share (%), 2027
  • Figure 4.1: Market Breakdown by Product: Revenue ($bn), Market Share (%), 2021
  • Figure 4.2: Market Breakdown by Product: Revenue ($bn), Market Share (%), 2027
  • Figure 4.3: Market Forecast by Product: Revenue ($bn), 2016-2027
  • Figure 4.4: Market Breakdown by Product: Revenue ($bn), 2016, 2021 and 2027
  • Figure 4.5: Lucentis: Revenues Forecast ($bn), 2016-2027
  • Figure 4.6: Drivers and Restraints for Lucentis, 2016
  • Figure 4.7: Eylea Forecast: Revenue ($bn), 2016-2027
  • Figure 4.8: Drivers and Restraints for Eylea, 2016
  • Figure 4.9: Avastin Forecast: Revenue ($bn), 2016-2027
  • Figure 4.10: Drivers and Restraints for Avastin, 2016
  • Figure 4.11: Visudyne Forecast: Revenues ($bn), 2016-2027
  • Figure 8.1: Regional Breakdown: Revenue ($bn), 2016-2027
  • Figure 8.2: Regional Breakdown: Revenue ($bn), 2016, 2021 and 2027
  • Figure 8.3: Regional Market Share (%), 2016
  • Figure 8.4: Regional Market Share (%), 2021
  • Figure 8.5: Regional Market Share (%), 2027
  • Figure 8.6: US Market: Revenue ($bn), 2016-2027
  • Figure 8.7: Japan: Revenue ($bn), 2016-2027
  • Figure 8.8: EU5: Grouped Revenue ($bn), 2016-2027
  • Figure 8.9: EU5 Breakdown Forecasts: Revenue ($bn), 2016-2027
  • Figure 8.10: EU5 Breakdown: Market Share (%), 2016
  • Figure 8.11: EU5 Breakdown: Market Share (%), 2021
  • Figure 8.12: EU5 Breakdown: Market Share (%), 2027
  • Figure 8.13: BRIC Nations Forecast: Grouped Revenue ($bn), 2016-2027
  • Figure 8.14: BRIC Nations Forecasts: Revenue ($bn), 2016-2027
  • Figure 8.15: Market Share (%) within BRIC Group by Country, 2016
  • Figure 8.16: Market Share (%) within BRIC Group by Country, 2021
  • Figure 8.17: Market Share (%) within BRIC Group by Country, 2027

List of Tables

  • Table 1.1: Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 1.2: Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2021-2027
  • Table 2.1: Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 2.2: Market Breakdown by Product: Revenue ($bn), Market Share (%), 2016
  • Table 3.1: Market Breakdown by Disease Segment: Revenue ($bn), Market Share (%), 2016
  • Table 3.2: Types of CNV in Wet AMD, Description: Approximate Proportion of Cases (%), 2016
  • Table 3.3: Wet AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2027
  • Table 3.4: Dry AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2027
  • Table 3.5: DR Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2016-2027
  • Table 3.6: Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 3.7: Retinal Diseases Market Forecasts by Segment: Revenue ($bn), Market Share (%) for 2016, 2021 and 2027
  • Table 4.1: Major Retinal Drugs Market Forecast: Revenue ($bn), CAGR (%) for 2016-2027
  • Table 4.10: Avastin Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 4.3: Market Breakdown by Product: Revenue ($bn), Market Share (%), 2027
  • Table 4.4: Lucentis: Revenue ($bn), AGR (%), 2012-2016
  • Table 4.5: Lucentis, Eylea and Avastin: Comparison of Reported Characteristics
  • Table 4.6: Lucentis: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 4.7: Eylea: Revenue ($bn), AGR (%), 2013-2016
  • Table 4.8: Eylea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 4.9: Avastin: Revenue ($bn), AGR (%), 2012-2014
  • Table 4.11: Visudyne Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 4.2: Market Breakdown by Product: Revenue ($bn), Market Share (%), 2021
  • Table 5.1: Selected R&D Pipeline (Phase 3) for wAMD, 2016
  • Table 5.2: Selected R&D Pipeline (Phase 2 & 1/2) for wAMD, 2016
  • Table 5.3: Selected R&D Pipeline (Phase 1) for wAMD, 2016
  • Table 6.1: Selected R&D Pipeline (Phase 2 & 3) for Dry AMD, 2016
  • Table 6.2: Selected R&D Pipeline (Phase 2 & 3) for Dry AMD, 2016
  • Table 7.1: Selected R&D Pipeline (Phase 2 & 3) for Diabetic Retinopathy, 2016
  • Table 7.2: Selected R&D Pipeline (Phase 1 & !/2) for Diabetic Retinopathy, 2016
  • Table 8.1: Regional Breakdown: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 8.1: Regional Breakdown: Revenue ($bn), AGR (%), CAGR (%), 2016-2027 (continued)
  • Table 8.2: US Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 8.3: Japan Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 8.4: EU5 Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 8.5: BRIC Nations Forecast: Revenue ($bn), AGR (%), CAGR (%), 2016-2027
  • Table 9.1: Strengths and Weaknesses in the AMD and Other Retinal Diseases Market, 2016
  • Table 9.2: Opportunities and Threats in the AMD and Other Retinal Diseases Market, 2016
  • Table 9.3: Social, Technological, Economic and Political Factors Influencing the AMD and Other Retinal Diseases Pharmaceutical Market (STEP Analysis), 2016-2027

Companies Listed

  • Abbott
  • Acucela
  • AgeX Therapeutics
  • Alcon
  • Alimera Sciences
  • Allegro Opthalmics
  • Allergan
  • Ampio Pharmaceuticals
  • Avalanche Biotechnologies
  • Bayer Healthcare
  • Bioeq GmbH
  • Biophytis
  • Biovail Corporation
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • CalTech
  • Cell Cure Neurosciences Ltd
  • Centocor
  • Chengdu Kanghong Biotech
  • Clearside Biomedical
  • CoMentis
  • Daiichi Sankyo
  • Diffusion Pharmaceuticals
  • Eli Lilly
  • ESBATech
  • Eye Gate Pharmaceuticals
  • ForSight Vision4
  • Gene Signal
  • Genentech
  • GlaxoSmithKline
  • Hemera Biosciences
  • Icon Bioscience
  • Iconic Therapeutics
  • Janssen Pharmaceuticals
  • Jiangsu T-mab BioPharma
  • Kala Pharmaceuticals
  • LPATH
  • MacuCLEAR
  • Mateon Therapeutics
  • Medical Need
  • Merck Sharp & Dohme
  • Mesoblast
  • Mitsubishi Tanabe Pharma
  • Molecular Partners
  • MorphoSys
  • Neuron Systems
  • Neurotech
  • Novartis
  • Novo Nordisk
  • Oakwood Laboratories
  • Ocata Therapeutics (Advanced Cell Technology)
  • OHR Pharmaceutical
  • Ophthotech Corporation
  • OpRegen (Biotime)
  • Opthea
  • Othera Pharmaceuticals
  • Otsuka Pharmaceutical
  • Oxford BioMedica
  • Oxigene
  • PanOptica
  • Pfenex
  • Pfizer
  • pSivida
  • Quark
  • Regenerative Patch Technologies
  • Regeneron/Bayer
  • Regenxbio
  • River Vision Development
  • Roche
  • RXi Pharmaceuticals
  • Sanofi
  • Santen Pharmaceutical
  • SciFluor Life Sciences
  • Senju Pharmaceutical
  • SGS Life Science Services
  • Stealth BioTherapeutics
  • StemCells
  • Stemedica Cell Technologies
  • SV Life Sciences
  • Third Rock Ventures
  • ThromboGenics
  • Tyrogenex
  • UCB
  • Valeant Pharmaceuticals
  • Xcovery Vision

List of Organisations

  • Association for Research in Vision and Ophthalmology
  • Columbia University
  • Germany's Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
  • International Diabetes Federation
  • Italian Competition Authority (ICA)
  • Japanese Ministry of Health, Labour and Welfare
  • NHS
  • NICE
  • Oregon Health and Science University
  • UK's General Medical Council
  • University College London (UCL)
  • US National Eye Institute
  • WHO
Back to Top